Hitherto unseen survival in an ALK ‐positive‐patient with advanced stage adult ganglioneuroblastoma treated with personalized medicine

Abstract

Survival of stage 4 ganglioneuroblastoma ( GNB ) patients is poor; no reports exist of patients surviving up to 5 years (1, 2). We report the clinical and therapeutic course of a patient with stage 4 GNB surviving beyond expectations due to a multimodal treatment approach incorporating new technologies in cancer diagnostic and treatment.